The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Aldo–keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer
Open accessAbstract
Aldo-keto reductase (AKR) 1C3 (type 5 17beta-hydroxysteroid dehydrogenase and prostaglandin F synthase), may stimulate proliferation via steroid hormone and prostaglandin (PG) metabolism in the breast. Purified recombinant AKR1C3 reduces PGD(2) to 9alpha,11beta-PGF(2), Delta(4)-androstenedione to testosterone, progesterone to 20alpha-hydroxyprogesterone, and to a lesser extent, estrone to 17beta-estradiol. We established MCF-7 cells that stably express AKR1C3 (MCF-7-AKR1C3 cells) to model its over-expression in breast cancer. AKR1C3 expression increased steroid conversion by MCF-7 cells, leading to a pro-estrogenic state. Unexpectedly, estrone was reduced fastest by MCF-7-AKR1C3 cells when compared to other substrates at 0.1muM. MCF-7-AKR1C3 cells proliferated three times faster than parental cells in response to estrone and 17beta-estradiol. AKR1C3 therefore represents a potential target for attenuating estrogen receptor alpha induced proliferation. MCF-7-AKR1C3 cells also reduced PGD(2), limiting its dehydration to form PGJ(2) products. The AKR1C3 product was confirmed as 9alpha,11beta-PGF(2) and quantified with a stereospecific stable isotope dilution liquid chromatography-mass spectrometry method. This method will allow the examination of the role of AKR1C3 in endogenous prostaglandin formation in response to inflammatory stimuli. Expression of AKR1C3 reduced the anti-proliferative effects of PGD(2) on MCF-7 cells, suggesting that AKR1C3 limits peroxisome proliferator activated receptor gamma (PPARgamma) signaling by reducing formation of 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In MCF-7 cells stably transfected with AKR1C3 it was found that the enzyme converts 0.1 μM estrone to 17β-estradiol faster than it catalyzes either the conversion of Δ4-androstene-3,17-dione to testosterone or the conversion of progesterone to 20α-hydroxy-pregn-4-ene-3-one”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 993
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649
Self-citationChemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Harris, R. E., Alshafie, G. A., Abou‐Issa, H., & Seibert, K. (2000) · PubMed · Cited by 486
The role of 17 beta-hydroxysteroid dehydrogenases
Mindnich, R., Möller, G., & Adamski, J. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.12.006 · Cited by 354
Labrie, F., Luu-The, V, Lin, S., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., & Belanger, A. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250001 · Cited by 278
Characteristics of a Highly Labile Human Type 5 17β-Hydroxysteroid Dehydrogenase1
Dufort, I., Rheault, P., Huang, X.-F., Soucy, P., & Luu-The, V. (1999) · Endocrinology · doi:10.1210/endo.140.2.6531 · Cited by 255
Shiraki, T., Kamiya, N., Shiki, S., Kodama, T. S., Kakizuka, A., & Jingami, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500901200 · Cited by 215
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-27 · Cited by 213
Sex steroid-producing enzymes in human breast cancer
Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., & Sasano, H. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00834 · Cited by 182
Matsuura, K., Shiraishi, H., Hara, A., Sato, K., Deyashiki, Y., Ninomiya, M., & Sakai, S. (1998) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022211 · Cited by 172
Cited by
Sorted by citations
The aldo-keto reductases (AKRs): Overview
Penning, T. M. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.09.024 · Cited by 565
Self-citationRole of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism
Rižner, T. L., & Penning, T. M. (2014) · Steroids · doi:10.1016/j.steroids.2013.10.012 · Cited by 217
Self-citationStructural and functional biology of aldo-keto reductase steroid transforming enzymes
Penning, T. M., Wangtrakuldee, P., & Auchus, R. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00089 · Cited by 164
Self-citationAldo-Keto Reductases and Cancer Drug Resistance
Penning, T. M., Jonnalagadda, S. K., Trippier, P. C., & Rižner, T. L. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000122 · Cited by 158
Self-citationInhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
Byrns, M. C., Jin, Y., & Penning, T. M. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.004 · Cited by 145
Self-citationChen, B., Zhang, Y., Wang, Y., Rao, J., Jiang, X., & Xu, Z. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.01.009 · Cited by 138
Complexities of androgen receptor signalling in breast cancer
McNamara, K. M., Moore, N. L. T., Hickey, T. E., Sasano, H., & Tilley, W. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0243 · Cited by 134
Penning, T. M. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.002 · Cited by 117
Self-citationMolecular therapy of breast cancer: progress and future directions
Lin, S., Chen, J., Mazumdar, M., Poirier, D., Wang, C., Azzi, A., & Zhou, M. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.92 · Cited by 119
Overview of AKR1C3: Inhibitor Achievements and Disease Insights
Liu, Y., He, S., Chen, Y., Liu, Y., Feng, F., Liu, W., Guo, Q., Zhao, L., & Sun, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02138 · Cited by 105
Matsunaga, T., Hojo, A., Yamane, Y., Endo, S., El-Kabbani, O. A. L., & Hara, A. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.09.024 · Cited by 98
Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
Penning, T. M. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1379503 · Cited by 96
Self-citationPenning, T. M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00319 · Cited by 98
Self-citationHofman, J., Malčeková, B., Skarka, A., Novotná, E., & Wsól, V. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.04.027 · Cited by 83
Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer
Rižner, T. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.026 · Cited by 76
Flanagan, J. U., Yosaatmadja, Y., Teague, R., Chai, M. Z. L., Turnbull, A. P., & Squire, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043965 · Cited by 71
Zub, K. A., de Sousa, M. M. L., Sarno, A., Sharma, A., Demirović, A., Rao, S. V., Young, C., Aas, P. A., Ericsson, I., Sundan, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119857 · Cited by 70
Cornel, K. M. C., Kruitwagen, R. F. P. M., Delvoux, B., Visconti, L. M., de Vijver, K. K. V., Day, J. M., Gorp, T. V., Hermans, R. J. J., Dunselman, G. A. J., & Romano, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2994 · Cited by 64
Hevir, N., Trošt, N., Debeljak, N., & Rižner, T. L. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.12.013 · Cited by 66
Zhong, T., Xu, F., Xu, J., Liu, L., & Chen, Y. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.12.022 · Cited by 66
Endo, S., Oguri, H., Segawa, J., Kawai, M., Hu, D., Xia, S., Okada, T., Irie, K., Fujii, S., Gouda, H., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00939 · Cited by 64
Byrns, M. C., Mindnich, R., Duan, L., & Penning, T. M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.12.012 · Cited by 60
Self-citationEbert, B., Kisiela, M., Wsól, V., & Maser, E. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.12.026 · Cited by 57
Byrns, M. C. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.01.015 · Cited by 55
Self-citationCross-Kingdom Actions of Phytohormones: A Functional Scaffold Exploration
Lin, L., & Tan, R. X. (2011) · Chemical Reviews · doi:10.1021/cr100061j · Cited by 54
Aldo-keto reductase 1C3—Assessment as a new target for the treatment of endometriosis
Rižner, T. L., & Penning, T. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104446 · Cited by 53
Self-citationXiong, W., Zhao, J., Yu, H., Li, X., Sun, S., Li, Y., Xia, Q., Zhang, C., He, Q., Gao, X., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111911 · Cited by 50
Endo, S., Matsunaga, T., Kanamori, A., Otsuji, Y., Nagai, H., Sundaram, K., El-Kabbani, O. A. L., Toyooka, N., Ohta, S., & Hara, A. (2012) · Journal of Natural Products · doi:10.1021/np201002x · Cited by 49
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases
Rižner, T. L. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00034 · Cited by 50
Hevir, N., Vouk, K., Šinkovec, J., Ribič-Pucelj, M., & Lanišnik Rižner, T. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2011.01.003 · Cited by 48
Oeste, C. L., & Pérez‐Sala, D. (2013) · Mass Spectrometry Reviews · doi:10.1002/mas.21383 · Cited by 48
In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis
Zhao, Y., Zheng, X., Zhang, H., Zhai, J. H., Zhang, L., Li, C., Zeng, K., Chen, Y., Li, Q., & Hu, X. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.09.006 · Cited by 46
Heinosalo, T., Saarinen, N., & POUTANEN, M. H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.08.004 · Cited by 40
PTHrP stimulates prostate cancer cell growth and upregulates aldo–keto reductase 1C3
Downs, T. M., Burton, D. W., Araiza, F., Hastings, R. H., & Deftos, L. J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.027 · Cited by 40
Mantel, A., Carpenter-Mendini, A. B., VanBuskirk, J., Benedetto, A. D., Beck, L. A., & Pentland, A. P. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.412 · Cited by 40
Retinaldehyde is a substrate for human aldo–keto reductases of the 1C subfamily
Ruiz, F. X., Porté, S., Gallego, O., Moro, A., Ardèvol, A., Río-Espínola, A. D., Rovira, C., Farrés, J., & Parés, X. (2011) · Biochemical Journal · doi:10.1042/bj20111286 · Cited by 38
Yoda, T., Kikuchi, K., Miki, Y., Onodera, Y., Hata, S., Takagi, K., Nakamura, Y., Hirakawa, H., Ishida, T., Suzuki, T., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.008 · Cited by 36
Kljun, J., Anko, M., Traven, K., Sinreih, M., Pavlič, R., Peršič, Š., Ude, Ž., Codina, E. E., Stojan, J., Rižner, T. L., et al. (2016) · Dalton Transactions · doi:10.1039/c6dt00668j · Cited by 36
Promiscuity and diversity in 3-ketosteroid reductases
Penning, T. M., Chen, M., & Jin, Y. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.12.003 · Cited by 36
Self-citationThe Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial Cancer
Sinreih, M., Knific, T., Anko, M., Hevir, N., Vouk, K., Jerin, A., Frković Grazio, S., & Rižner, T. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00368 · Cited by 33
AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies
Li, M., Zhang, L., Yu, J., Wang, X., Cheng, L., Ma, Z., Chen, X., Wang, L., & Goh, B. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1378292 · Cited by 36
Yin, Y. D., Fu, M., Brooke, D. G., Heinrich, D. M., Denny, W. A., & Jamieson, S. M. F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00159 · Cited by 33
Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors
Zemanová, L., Hofman, J., Chlebek, J., Havrankova, J., Kosanova, K., Skarka, A., Hošťálková, A., Plucha, T., Cahlíková, L., & Wsól, V. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.04.005 · Cited by 32
Miller, V. L., Lin, H.-K., Murugan, P., Fan, M. D., Penning, T. M., Brame, L. S., Yang, Q., & Fung, K.-M. A. (2012) · Europe PMC (PubMed Central) · Cited by 32
Self-citationBrožič, P., Turk, S., Adeniji, A. O., Konc, J., Janežič, D., Penning, T. M., Rižner, T. L., & Gobec, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300841n · Cited by 30
Self-citationEndo, S., Hu, D., Matsunaga, T., Otsuji, Y., El-Kabbani, O. A. L., Kandeel, M. K., Ikari, A., Hara, A., Kitade, Y., & Toyooka, N. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.08.007 · Cited by 29
Sekine, Y., Nakayama, H., Miyazawa, Y., Kato, H., Furuya, Y., Arai, S., Koike, H., Matsui, H., Shibata, Y., Ito, K., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7721 · Cited by 29
AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas
Hojnik, M., Šuster, N. K., Smrkolj, Š., Grazio, S. F., Verdenik, I., & Rižner, T. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124105 · Cited by 26
Chu, X., He, S., Liu, Y., Liu, Y., Feng, F., Guo, Q., Zhao, L., & Sun, H. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109746 · Cited by 31
Aldo-keto reductases: Role in cancer development and theranostics
Nagini, S., Kallamadi, P. R., Tanagala, K. K. K., & Reddy, G. B. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.049918 · Cited by 28
Aldo-keto reductase (AKR) superfamily website and database: An update
Huacachino, A. A., Joo, J., Narayanan, N., Tehim, A., Himes, B. E., & Penning, T. M. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111111 · Cited by 27
Self-citationAKR1C3 Overexpression Mediates Methotrexate Resistance in Choriocarcinoma Cells
Zhao, J., Xiang, Y., Xiao, C., Guo, P., Wang, D., Liu, Y., & Shen, Y. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.9239 · Cited by 25
Role of Aldo–Keto Reductase Enzymes in Mediating the Timing of Parturition
Byrns, M. C. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00092 · Cited by 24
Self-citationChewchuk, S., Guo, B., & Parissenti, A. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172244 · Cited by 23
Matsunaga, T., Okumura, N., Saito, H., Morikawa, Y., Suenami, K., Hisamatsu, A., Endo, S., & Ikari, A. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109295 · Cited by 22
He, S., Chu, X., Wu, Y., Jiang, J., Fang, P., Chen, Y., Liu, Y., Qiu, Z., Xiao, Y., Li, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00213 · Cited by 21
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells
Doig, C. L., Battaglia, S., Khanim, F. L., Bunce, C. M., & Campbell, M. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.09.037 · Cited by 21
Li, W., Hou, G., Zhou, D., Lou, X., Xu, Y., Liu, S., & Zhao, X. (2016) · Oncotarget · doi:10.18632/oncotarget.7775 · Cited by 21
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
Büküm, N., Novotná, E., Morell, A., Hofman, J., & Wsól, V. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.01.026 · Cited by 20
Mantel, A., Carpenter-Mendini, A. B., VanBuskirk, J., & Pentland, A. P. (2014) · Experimental Dermatology · doi:10.1111/exd.12468 · Cited by 20
Transcript level of AKR1C3 is down-regulated in gastric cancer
Frycz, B. A., Murawa, D., Borejsza‐Wysocki, M., Wichtowski, M., Spychała, A., Marciniak, R., Murawa, P., Drews, M., & Jagodziński, P. P. (2015) · Biochemistry and Cell Biology · doi:10.1139/bcb-2015-0096 · Cited by 19
Morell, A., Čermáková, L., Novotná, E., Laštovičková, L., Haddad, M., Haddad, A., Portillo, R., & Wsól, V. (2020) · Cancers · doi:10.3390/cancers12123731 · Cited by 17
Mantel, A., Newsome, A., Thekkudan, T., Frazier, R., & Katdare, M. (2015) · Experimental Dermatology · doi:10.1111/exd.12854 · Cited by 16
Dehydroepiandrosterone (DHEA)-SO 4 Depot and Castration-Resistant Prostate Cancer
Penning, T. M. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.01.007 · Cited by 16
Self-citationAnalogues of Natural Chalcones as Efficient Inhibitors of AKR1C3
Möller, G., Temml, V., Cala, A., Gruet, O., Richomme, P., Séraphin, D., Viault, G., Kraus, L., Huber‐Cantonati, P., Schopfhauser, E., et al. (2022) · Metabolites · doi:10.3390/metabo12020099 · Cited by 16
Xia, D., Lai, D. V., Wu, W., Webb, Z. D., Yang, Q., Zhao, L., Yu, Z., Thorpe, J. E., Disch, B. C., Ihnat, M. A., et al. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.11.006 · Cited by 15
Kulkarni, S., Singh, Y., Biharee, A., Bhatia, N., Monga, V., & Thareja, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2175265 · Cited by 14
Deletion of Alox15 improves kidney dysfunction and inhibits fibrosis by increased PGD2 in the kidney
Takahashi, N., Kikuchi, H., Usui, A., Furusho, T., Fujimaru, T., Fujiki, T., Yanagi, T., Matsuura, Y., Asano, K., Yamamoto, K., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02021-y · Cited by 14
Sausville, L. N., Jones, C. C., Aldrich, M. C., Blot, W. J., Pozzi, A., & Williams, S. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180471 · Cited by 12
Sali, V. K., Mani, S., Meenaloshani, G., Ilavarasi, A. V., & Vasanthi, H. R. (2020) · Steroids · doi:10.1016/j.steroids.2020.108638 · Cited by 13
Detlefsen, A. J., Wangtrakuldee, P., & Penning, T. M. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106121 · Cited by 12
Self-citationMorell, A., Budagaga, Y., Vagiannis, D., Zhang, Y. X., Laštovičková, L., Novotná, E., Haddad, A., Haddad, M., Portillo, R., Hofman, J., et al. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03359-2 · Cited by 12
Huang, C., Li, F. X., Pan, S., Xu, C., Dai, J. Q., & Zhao, X. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7488 · Cited by 12
The role of 17βHSDs in breast tissue and breast cancers
McNamara, K. M., & Sasano, H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.019 · Cited by 12
Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma
Xing, S., Jiang, J., Chu, X., Wang, X., Wang, Z., Li, X., Lv, B., Guo, C., He, S., Wang, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03035 · Cited by 11
Gazvoda, M., Beranič, N., Turk, S., Burja, B., Kočevar, M., Rižner, T. L., Gobec, S., & Polanc, S. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.045 · Cited by 11
Instability of C154Y variant of aldo-keto reductase 1C3
Endo, S., Takada, S., Honda, R. P., Müller, K., Weishaupt, J. H., Andersen, P. M., Ludolph, A. C., Kamatari, Y. O., Matsunaga, T., Kuwata, K., et al. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.12.018 · Cited by 11
Gao, L., Bao, Z., Deng, H., Li, X., Li, J., Rong, Z., Yang, Y., Liu, L., Nie, D., Wang, G., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1724-9 · Cited by 11
New enzymatic assay for the AKR1C enzymes
Beranič, N., Štefane, B., Brus, B., Gobec, S., & Rižner, T. L. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.12.003 · Cited by 11
Zhang, C., Min, Z., Liu, X., Wang, C., Wang, Z., Shen, J., Tang, W., Zhang, X., Liu, D., & Xu, X. (2019) · FEBS Letters · doi:10.1002/1873-3468.13630 · Cited by 10
Janković, Ð. D., Šestić, T. L., Bekić, S. S., Savić, M. P., Ćelić, A. S., Scholda, J., Kopp, F. B., Marinović, M. A., Petri, E. T., & Ajduković, J. J. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106545 · Cited by 9
Morell, A., Novotná, E., Milan, J., Danielisová, P., Büküm, N., & Wsól, V. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02884-2 · Cited by 10
Shi, T., Fan, Q., Liu, S., & Zhang, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116309 · Cited by 8
Čermáková, L., Hofman, J., Laštovičková, L., Havlíčková, L., Špringrová, I., Novotná, E., & Wsól, V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101994 · Cited by 8
Jia, Y., Domenico, J. M., Swasey, C. H., Wang, M., Gelfand, E. W., & Lucas, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097448 · Cited by 8
Matsunaga, T., Hosogai, M., Arakaki, M., Endo, S., El-Kabbani, O. A. L., & Hara, A. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00237 · Cited by 7
Fonseca-Benítez, A. V., Acosta‐Guzmán, P., Sánchez, J. E., Alarcón, Z., Jiménez, R. A., & Guevara‐Pulido, J. O. (2024) · Molecules · doi:10.3390/molecules29081802 · Cited by 6
Xing, S., Liu, Y., Xie, H., Guo, C., Wang, X., Lv, B., Li, X., Shao, J., Guo, Q., Feng, F., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117413 · Cited by 5
Deciphering 17-β-hydroxysteroid dehydrogenase 4: from molecular insights to cancer therapeutics
Liao, M.-B., Lau, A. T. Y., & Xu, Y. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03885-w · Cited by 4
Downregulation of Dihydrotestosterone and Estradiol Levels by HEXIM1
Mozar, F. S., Sharma, V., Gorityala, S., Albert, J. M., Xu, Y., & Montano, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab236 · Cited by 4
The Aldo-Keto Reductase Superfamily
Penning, T. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64092-8 · Cited by 4
Self-citationZiogas, M., Siefer, O. G., Wuerdemann, N., Balaji, H., Gross, E., Drebber, U., Klußmann, J. P., & Huebbers, C. U. (2024) · Cancers · doi:10.3390/cancers16172976 · Cited by 3
Jin, D.-D., He, Y., Ran, F., Hong-yuan, Y., Yan, G., & Yang, Z. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112581 · Cited by 3
Juvinao-Quintero, D. L., Sánchez, S. E., Workalemahu, T., Pinto, N., Liang, L., Williams, M. A., & Gelaye, B. (2024) · Journal of Neonatal-Perinatal Medicine · doi:10.3233/npm-230228 · Cited by 3
Catalytic characteristics of AKR1C1-AKR1C4 and AKR1C9 on oxymesterone
Hu, H., Li, S., Zhang, C., Li, L., Yang, J., Wu, Q., Ou, L., You, J., Sun, A., Wieland, F. H., et al. (2024) · Molecular Catalysis · doi:10.1016/j.mcat.2024.114256 · Cited by 2
Environmental Lead Promotes Breast Cancer Migration and Invasion via the AKR1C3–NF-κB–MMP Axis
Liu, J., Ding, Y., Qiao, L., Meng, R., Shi, S., Zhang, Y., Liu, Y., Liu, S., Liu, Y., He, X., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14020286 · Cited by 2
Khalilullah, H. (2021) · ChemistrySelect · doi:10.1002/slct.202103151 · Cited by 2
Phthalate-treated endometrial cancer cell lines show increased AKR1C1 expression
Song, J.-Y., & Cho, H. (2014) · Molecular & Cellular Toxicology · doi:10.1007/s13273-014-0042-7 · Cited by 2
Identification of significantly mutated subnetworks in the breast cancer genome
Ajwad, R., Domaratzki, M., Liu, Q., Feizi, N., & Hu, P. (2021) · Scientific Reports · doi:10.1038/s41598-020-80204-5 · Cited by 2
Basu, T., & Upadhyay, A. K. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2241543 · Cited by 1
Metadata
- Authors
- Byrns, M. C., Duan, L., Lee, S. H., Blair, I. A., & Penning, T. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Penning, Trevor M.
- Venue
- The Journal of Steroid Biochemistry and Molecular Biology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 118
- Issue
- 3
- Pages
- 177-187
- ISSN
- 0960-0760 (ISSN-L)
- PMC
- PMC2819162
- OpenAlex
- W1984703484
- Cited by
- 116
- References
- 45
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 11 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 5 · 2015: 7 · 2014: 14 · 2013: 5 · 2012: 11
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Steroid Biochemistry and Molecular Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (22590130)
- National Cancer Institute (R01CA090744)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007314)
- National Institute of Environmental Health Sciences (U01ES016004, P30ES013508)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD007305)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- AKR1C3, MCF-7 cells, breast cancer, steroid hormone metabolism, prostaglandin metabolism, prostaglandin F2alpha, estrogen metabolism, estrone, estradiol, cell proliferation, estrogen receptor alpha, PPARγ signaling
- MeSH terms
- Aldo-Keto Reductase Family 1 Member C3, Androstenedione, Androsterone, Breast Neoplasms, 20-alpha-Dihydroprogesterone, Estradiol, Estrone, Etiocholanolone, Female, Humans, Hydroxyprostaglandin Dehydrogenases, Ketosteroids, Kinetics, Progesterone, Prostaglandins, Recombinant Proteins, Gonadal Steroid Hormones, Dihydrotestosterone, Testosterone, Transfection, 3-Hydroxysteroid Dehydrogenases, Prostaglandin D2, Dinoprost, Up-Regulation, Gene Expression Regulation, Neoplastic, 5-alpha-Dihydroprogesterone, Cell Line, Tumor, Cell Proliferation, Biocatalysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
